Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5909.092 | 0.0070 | -0.6100 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5909.092 | 0.0018 | -0.7507 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5910.091 | 1.0679 | 1.0399 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5910.091 | 1.0941 | 1.0549 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5910.091 | 1.0535 | 1.0316 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5910.091 | 1.0418 | 1.0248 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5910.091 | 1.1442 | 1.0828 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5910.091 | 0.9750 | 0.9848 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5910.091 | 0.7607 | 0.8419 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5910.091 | 0.0016 | -0.7134 | 3.3208 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5910.091 | 0.0014 | -0.7258 | 3.3208 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5911.09 | 0.9975 | 0.9954 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5911.09 | 0.9529 | 0.9147 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5911.09 | 0.9840 | 0.9710 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5911.09 | 0.9609 | 0.9292 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5911.09 | 0.9567 | 0.9216 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5911.09 | 0.9657 | 0.9380 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5911.09 | 0.5505 | 0.1662 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5911.09 | 0.0108 | -0.9667 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5911.09 | 0.0092 | -0.9710 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5912.091 | 0.9899 | 0.9815 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5912.091 | 1.0558 | 1.1021 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5912.091 | 0.9948 | 0.9905 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5912.091 | 1.0026 | 1.0048 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5912.091 | 1.0087 | 1.0160 | 1.0917 |